Fig. 8

| TVB-3166 inhibited BLCA progression and reversed gemcitabine resistance. A, B Cell viability and sensitivity to gemcitabine under all conditions were determined by CCK-8 assay. C The tumorigenic ability of single cells under all conditions was determined by colony formation assay. D, E The lipid content of gemcitabine-resistant cells after treatment with TVB-3166 was quantitatively detected by BODIPY staining corrected total cell fluorescence (CTCF) and the contents of free fatty acids (FFAs), triglycerides (TGs) and total cholesterol (T-CHO). F, G, and H The mice were divided into 4 groups with 5 mice in each group: Group I (DMSO: DMSO), group II (DMSO: gemcitabine), group III (DMSO: TVB-3166) and group IV (gemcitabine: TVB-3166). Tumor volumes were measured every 5 days (n = 5 per group). Tumors were weighed after resection. The graphs show the means ± SEMs. One-way ANOVA followed by Tukey’s multiple comparison test. α = 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****p < 0.0001; ns, no significance. I Enzyme-linked immunosorbent assay (ELISA) was used to determine the FASN content of xenograft tumors in each group. J Statistical analysis was performed on the rate of KI67- and TUNEL-positive cells in each group of xenograft tumors by immunohistochemical staining (IHC). The corrected total cell fluorescence (CTCF) of BODIPY staining was used to quantitatively detect the lipid content of xenograft tumors in each group. Representative images are shown